# Summary
Purdue Pharma's settlement agreement will exclude many opioid victims from receiving compensation despite years of litigation and suffering. The bankruptcy settlement, which resolves claims against the company for its role in the opioid crisis, contains eligibility restrictions that bar certain plaintiffs from recovery.
Victims who waited through extended legal proceedings now face rejection based on specific settlement terms. The restrictions prevent access to funds for those whose claims fall outside narrowly defined parameters. This outcome frustrates plaintiffs who endured lengthy delays anticipating financial relief.
The settlement structure prioritizes certain categories of claimants while leaving others without recourse. Eligible parties will receive compensation from the settlement fund, but excluded victims have limited options for recovery. Legal experts note the restrictions conflict with the original intent to compensate those harmed by Purdue's marketing and distribution practices.
The decision reflects ongoing tensions in mass tort settlements between defendants seeking closure and plaintiffs seeking comprehensive relief. State attorneys general and individual claimants have criticized the eligibility limitations as inadequate. Purdue's settlement resolves billions in liability while leaving some victims without compensation despite their documented injuries and losses from opioid addiction and overdoses.